So Undervalued. Imo, stock will be soon over $10+ Major accumulation is occuring and the news flow has started. The move can be very fast from this point on.
Value will be released from the shackles when there is concrete data showing improvement - including that from the extended trials. That would justify the case for extending the trial.
It would be nice to show how extension has benefited either by providing further improvement or at least maintaining the level of improvement recorded at the end of regular trial.(Comparison of data before starting trial vs after the normal duration of trial vs after extension of trial).
The AD trial with extension is now close to 208 weeks. That is enough time (unprecedented) for a disease like AD. At some point in time they have to stop extending the trials and process all data for Wall Street to be humbled.
Not sure if TGA is waiting on that to sign off on PA.
News 
Market Data 
Discover 
